Table 3.
Psychoactive substance use characteristics at baseline measurement.
| Category, substance, and characteristics | App group | Nonapp group | Significancea (app vs nonapp group) | Effect size, r | ||||
|
|
|
|
VS1b | HS1c | VS2d | HS2e |
|
|
| Legal substances, n (%) | ||||||||
|
|
Alcohol | |||||||
|
|
|
Lifetime use | 123 (92.5) | 94 (88.7) | 60 (92.3) | 57 (95) | χ21=0.9 | .05 |
|
|
|
Last month | 65 (56) | 53 (50.5) | 33 (55.9) | 40 (67.8) | χ21=2.2 | .08 |
|
|
Tobacco | |||||||
|
|
|
Lifetime use | 77 (52) | 84 (77.6) | 42 (59.2) | 50 (83.3) | χ21=2.1 | .07 |
|
|
|
Last month use | 35 (45.5) | 20 (24.1) | 16 (38.1) | 12 (24) | χ21=0.4 | .04 |
| Illegal substances, n (%) | ||||||||
|
|
Cannabis | |||||||
|
|
|
Lifetime use | 14 (13.1) | 14 (14.1) | 10 (17.2) | 5 (8.5) | χ21=0.0 | .01 |
|
|
|
Last month use | 2 (1.9) | 7 (7.1) | 4 (6.9) | 1 (1.7) | χ21=0.0 | .001 |
|
|
Ecstasy | |||||||
|
|
|
Lifetime use | 3 (2.8) | 0 (0) | 6 (10.3) | 1 (1.7) | P=.04f | N/Ag |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
Amphetamines | |||||||
|
|
|
Lifetime use | 2 (1.9) | 1 (1) | 3 (5.2) | 1 (1.7) | P=.26 | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
Cocaine | |||||||
|
|
|
Lifetime use | 1 (0.9) | 0 (0) | 5 (8.6) | 1 (1.7) | P=.01h | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
LSDi/Magic mushroom | |||||||
|
|
|
Lifetime use | 3 (2.8) | 1 (1) | 4 (6.9) | 0 (0) | P=.47 | N/A |
|
|
|
Last month use | 2 (1.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.63 | N/A |
|
|
Heroin | |||||||
|
|
|
Lifetime use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 3.4) | 0 (0) | P=.56 | N/A |
| NPSj-type substances, n (%) | ||||||||
|
|
GHBk | |||||||
|
|
|
Lifetime use | 2 (1.9) | 0 (0) | 3 (5.2) | 0 (0) | P=.36 | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 3 (5.2) | 0 (0) | P=.14 | N/A |
|
|
Mephedrone | |||||||
|
|
|
Lifetime use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
Pentedrone | |||||||
|
|
|
Lifetime use | 2 (1.9) | 0 (0) | 3 (5.3) | 0 (0) | P=.36 | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 (3.5) | 0 (0) | P=.30 | N/A |
|
|
MDPVl | |||||||
|
|
|
Lifetime use | 5 (4.7) | 0 (0) | 3 (5.2) | 0 (0) | P=.99 | N/A |
|
|
|
Last month use | 1 (0.9) | 0 (0) | 2 (3.4) | 0 (0) | P=.56 | N/A |
|
|
Synthetic cannabinoids | |||||||
|
|
|
Lifetime use | 6 (5.7) | 4 (4.2) | 8 (13.8) | 3 (5.1) | P=.16 | N/A |
|
|
|
Last month use | 1 (0.9) | 1 (1) | 4 (6.9) | 0 (0) | P=.19 | N/A |
aχ2 test or Fisher exact test.
bVS1: vocational school 1.
cHS1: high school 1.
dVS2: vocational school 2.
eHS2: high school 2.
fP<.05.
gN/A: not applicable.
hP<.01.
iLSD: lysergic acid diethylamide.
jNPS: novel psychoactive substance.
kGHB: gamma-hydroxybutyrate.
lMDPV: methylenedioxypyrovalerone.